N-Acetylcysteine amide protects against methamphetamine-induced tissue damage in CD-1 mice

Human and Experimental Toxicology

Volumn 31, Issue 9, 2012, Pages 931-944

  Zhang, X ^a   Tobwala, S ^a   Ercal, N ^a  

^a MISSOURI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (United States)

Author keywords

antioxidant; methamphetamine; N acetylcysteine amide; oxidative stress; reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; CARBONYL DERIVATIVE; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; METHAMPHETAMINE; PROTEIN CARBONYL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TISSUE INJURY;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; BRAIN; CATALASE; CENTRAL NERVOUS SYSTEM STIMULANTS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; KIDNEY; LIPID PEROXIDATION; LIVER; MALE; MALONDIALDEHYDE; METHAMPHETAMINE; MICE; OXIDATIVE STRESS; PROTEIN CARBONYLATION;

ANIMALIA; MUS;

EID: 84866483825     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327112438287     Document Type: Article

References (100)

1. Office of Applied Studies. Primary Methamphetamine/Amphetamine Treatment Admissions: 1992-2002. The DASIS Report. 2004http://www.oas.samhsa.gov/facts. cfm.
2. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration ; 2006 :
3. Rockville, MD: Substance Abuse and Mental Health Services Administration ; 2007 :
4. Rockville, MD: Substance Abuse and Mental Health Services Administration ; 2003 :
5. Gonzales R, Mooney L, Rawson RA. The methamphetamine problem in the United States. Annu Rev Publ Health. 2010 ; 31: 385-398
6. Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci. 1999 ; 44: 359-368
7. Richards JR. Rhabdomyolysis and drugs of abuse. J Emerg Med. 2000 ; 19: 51-56
8. Kendrick WC, Hull AR, Knochel JP. Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Intern Med. 1977 ; 86: 381-387
9. Richards JR, Johnson EB, Stark RW, Derlet RW. Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med. 1999 ; 17: 681-685
10. Terada Y, Shinohara S, Matui N, Ida T. Amphetamine-induced myoglobinuric acute renal failure. Jpn J Med. 1988 ; 27: 305-308
11. Holt S, Moore K. Pathogenesis of renal failure in rhabdomyolysis: the role of myoglobin. Exp Nephrol. 2000 ; 8: 72-76
12. Ramcharan S, Meenhorst PL, Otten JM, Koks CH, de Boer D, Maes RA, et al. Survival after massive ecstasy overdose. J Toxicol Clin Toxicol. 1998 ; 36: 727-731
13. Lan KC, Lin YF, Yu FC, Lin CS, Chu P. Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc. 1998 ; 97: 528-533
14. Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharm Ther. 1999 ; 13: 129-133
15. Hall AP, Henry JA. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Brit J Anaesth. 2006 ; 96: 678-685
16. Jones AL, Jarvie DR, McDermid G, Proudfoot AT. Hepatocellular damage following amphetamine intoxication. J Toxicol Clin Toxicol. 1994 ; 32: 435-444
17. Carvalho F, Remião F, Soares ME, Catarino R, Queiroz G, Bastos ML.. d-Amphetamine-induced hepatotoxicity: possible contribution of catecholamines and hyperthermia to the effect studied in isolated rat hepatocytes. Arch Toxicol. 1997 ; 71: 429-436
18. Zalis EG, Lundberg GD, Knutson RA. The pathophysiology of acute amphetamine poisoning with pathologic correlation. J Pharm Exp Ther. 1967 ; 158: 115-127
19. Mooney LJ, Glasner-Edwards S, Rawson RA, Ling W Methamphetamine addiction: From basic science to treatment. Roll JM Rawson RA Ling W and Shoptaw S, ed. New York, NY: The Guilford Press ; 2009: 117-142.
20. Yu Q, Larson D, Watson RR. Heart disease, methamphetamine and AIDS. Life Sci. 2003 ; 73: 129-140
21. Derlet RW, Horowitz BZ. Cardiotoxic drugs. Emerg Med Clin N Am. 1995 ; 13: 771-791
22. Albertson TE, Derlet RW, Van Hoozen BE. Methamphetamine and the expanding complications of amphetamines. Western J Med. 1999 ; 170: 214-219
23. Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008 ; 27: 253-262
24. Perez JAJ, Arsura EL, Strategos S. Methamphetamine-related stroke: four cases. J Emerg Med. 1999 ; 17: 469-471
25. Homer BD, Solomon TM, Moeller RW, Mascia A, DeRaleau L, Halkitis PN. Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull. 2008 ; 134: 301-310
26. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev. 2007 ; 17: 275-297
27. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, et al. Psychiatric symptoms in methamphetamine users. Am J Addiction. 2004 ; 13: 181-190
28. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009 ; 197: 225-231
29. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harvard Rev Psychiat. 2005 ; 13: 141-154
30. Cubells JF, Rayport S, Rajendran G, Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci. 1994 ; 14: 2260-2271
31. De Vito MJ, Wagner GC. Methamphetamine- induced neuronal damage: a possible role for free radicals. Neuropharmacology. 1989 ; 28: 1145-1150
32. Itzhak Y, Ali SF. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem. 1996 ; 67: 1770-1773
33. Itzhak Y, Gandia C, Huang PL, Ali SF. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. J Pharmacol Exp Ther. 1998 ; 284: 1040-1047
34. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 1980 ; 181: 151-160
35. Kita T, Wagner GC, Nakashima T. Current research on methamphetamine- induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci. 2003 ; 92: 178-195
36. Zhang X, Banerjee A, Banks WA, Ercal N. N-Acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells. Brain Res. 2009 ; 1275: 87-95
37. Harold C, Wallace T, Friedman R, Gudelsky G, Yamamoto B. Methamphetamine selectively alters brain glutathione. Eur J Pharmacol. 2000 ; 400: 99-102
38. Moszczynska A, Turenne S, Kish SJ. Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine. Neurosci Lett. 1998 ; 255: 49-52
39. Chen H, Lee Y, Huang C, Liu H, Liao W, Lai W, et al. Methamphetamine downregulates peroxiredoxins in rat pheochromocytoma cells. Biochem Biophys Res Commun. 2007 ; 354: 96-101
40. D'Almeida V, Camarini R, Azzalis LA, Mattei R, Junqueira VB, Carlini EA. Antioxidant defense in rat brain after chronic treatment with anorectic drugs. Toxicol Lett. 1995 ; 81: 101-105
41. Iwazaki T, McGregor IS, Matsumoto I. Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Res. 2006 ; 1097: 19-25
42. Jayanthi S, Ladenheim B, Cadet JL. Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice. Ann N Y Acad Sci. 1998 ; 844: 92-102
43. Kobeissy FH, Warren MW, Ottens AK, Sadasivan S, Zhang Z, Gold MS, et al. Psychoproteomic analysis of rat cortex following acute methamphetamine exposure. J Proteome Res. 2008 ; 7: 1971-1983
44. Li X, Wang H, Qiu P, Luo H. Proteomic profiling of proteins associated with methamphetamine-induced neurotoxicity in different regions of rat brain. Neurochem Int. 2008 ; 52: 256-264
45. Açikgöz O, Gönenç S, Kayatekin BM, Uysal N, Pekçetin C, Semin I, et al. Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum. Brain Res. 1998 ; 813: 200-202
46. Gluck MR, Moy LY, Jayatilleke E, Hogan KA, Manzino L, Sonsalla PK. Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem. 2001 ; 79: 152-160
47. Melo P, Rodrigues LG, Pinazo-Durán MD, Tavares MA. Methamphetamine and lipid peroxidation in the rat retina. Birth Defects Res A. 2005 ; 73: 455-460
48. Tokunaga I, Kubo S, Ishigami A, Gotohda T, Kitamura O. Changes in renal function and oxidative damage in methamphetamine-treated rat. Legal Med. 2006 ; 8: 16-21
49. Shan XQ, Aw TY, Jones DP. Glutathione-dependent protection against oxidative injury. Pharmacol Therap. 1990 ; 47: 61-71
50. Penugonda S, Mare S, Goldstein G, Banks WA, Ercal N. Effects of N-acetylcysteine amide (NACA), a novel thiol antioxidant against glutamate-induced cytotoxicity in neuronal cell line PC12. Brain Res. 2005 ; 1056: 132-138
51. Wu W, Abraham L, Ogony J, Matthews R, Goldstein G, Ercal N. Effects of N-acetylcysteine amide (NACA), a thiol antioxidant on radiation-induced cytotoxicity in Chinese hamster ovary cells. Life Sci. 2008 ; 82: 1122-1130
52. Price TO, Uras F, Banks WA, Ercal N. A novel antioxidant N-acetylcysteine amide prevents gp120- and Tat-induced oxidative stress in brain endothelial cells. Exp Neurol. 2006 ; 201: 193-202
53. Amer J, Atlas D, Fibach E. N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells. Biochim Biophys Acta. 2008 ; 1780: 249-255
54. Grinberg L, Fibach E, Amer J, Atlas D. N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress. Free Radic Biol Med. 2005 ; 38: 136-145
55. Shrem MT, Halkitis PN. Methamphetamine abuse in the United States: contextual, psychological and sociological considerations. J Health Psychol. 2008 ; 13: 669-679
56. Madden LJ, Flynn CT, Zandonatti MA, May M, Parsons LH, Katner SN, et al. Modelling human methamphetamine exposure in nonhuman primates: Chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities. Neuropsychopharmacology. 2005 ; 30: 350-359
57. Winters RA, Zukowski J, Ercal N, Matthews RH, Spitz DR. Analysis of glutathione, glutathione disulfide, cysteine, homocysteine, and other biological thiols by high-performance liquid chromatography following derivatization by n-(1-pyrenyl)maleimide. Anal Biochem. 1995 ; 227: 14-21
58. Draper HH, Squires EJ, Mahmoodi H, Wu J, Agarwal S, Hadley M. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic Biol Med. 1993 ; 15: 353-363
59. Aebi H. Catalase in vitro. Method Enzymol. 1984 ; 105: 121-126
60. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, et al. Determination of carbonyl content in oxidatively modified proteins. Method Enzymol. 1990 ; 186: 464-478
61. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 ; 72: 248-254
62. Burrows KB, Yamamoto BK. Glutamate and addiction. Herman BH, ed. New Jersey, NJ: Humana Press Inc ; 2003: 211-227.
63. Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse. 1994 ; 17: 203-209
64. Melo P, Pinazo-Durán MD, Salgado-Borges J, Tavares MA. Correlation of axon size and myelin occupancy in rats prenatally exposed to methamphetamine. Brain Res. 2008 ; 1222: 61-68
65. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996 ; 379: 606-612
66. Golembiowska K, Zylewska A. Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Res. 1998 ; 806: 202-209
67. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol. 1978 ; 14: 633-643
68. Stumm G, Schlegel J, Schäfer T, Würz C, Mennel HD, Krieg JC, et al. Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J. 1999 ; 13: 1065-1072
69. Matsumoto RR, Liu Y, Lerner M, Howard EW, Brackett DJ. Sigma receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol. 2003 ; 469: 1-12
70. Bellomo G, Mirabelli F, Richelmi P, Malorni W, Iosi F, Orrenius S. The cytoskeleton as a target in quinone toxicity. Free Radic Res Commun. 1990 ; 8: 391-399
71. Nicotera P, Bellomo G, Orrenius S. Calcium-mediated mechanisms in chemically induced cell death. Ann Rev Pharmacol Toxicol. 1992 ; 32: 447-470
72. Nakagawa Y, Suzuki T, Tayama S, Ishii H, Ogata A. Cytotoxic effects of 3,4-ethylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Arch Toxicol. 2009 ; 83: 69-80
73. Ishigami A, Tokunaga I, Gotohda T, Kubo S. Immunohistochemical study of myoglobin and oxidative injury related markers in the kidney of methamphetamine abusers. Legal Med. 2003 ; 5: 42-48
74. Orlowski M, Meister A. Isolation of highly purified gamma- glutamylcysteine synthetase from rat kidney. Biochemistry. 1971 ; 10: 372-380
75. Palekar AG, Tate SS, Meister A. Decrease in glutathione levels of kidney and liver after injection of methionine sulfoximine into rats. Biochem Biophys Res Commun. 1975 ; 62: 651-657
76. Achat-Mendes C, Anderson KL, Itzhak Y. Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists. Neuropsychopharmacology. 2007 ; 32: 531-541
77. Açikgöz O, Gönenç S, Gezer S, Kayatekin BM, Uysal N, Semin I, et al. Methamphetamine causes depletion of glutathione and an increase in oxidized glutathione in the rat striatum and prefrontal cortex. Neurotoxicol Res. 2001 ; 3: 277-280
78. Kim HC, Jhoo WK, Choi DY, Im DH, Shin EJ, Suh JH, et al. Protection of methamphetamine nigrostriatal toxicity by dietary selenium. Brain Res. 1999 ; 851: 76-86
79. Flora G, Lee YW, Nath A, Maragos W, Hennig B, Toborek M. Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromol Med. 2002 ; 2: 71-85
80. Issels RD, Nagele A, Eckert KG, Wilmanns W. Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine. Biochem Pharmacol. 1988 ; 37: 881-888
81. Karbownik M, Reiter RJ.. Antioxidative effects of melatonin in protection against cellular damage caused by ionizing radiation. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine (New York, NY).. 2000 ; 225: 9-22
82. Açikgöz O, Gönenç S, Kayatekin BM, Pekçetin C, Uysal N, Dayi A, et al. The effects of single dose of methamphetamine on lipid peroxidation levels in the rat striatum and prefrontal cortex. Eur Neuropsychopharmacol. 2000 ; 10: 415-418
83. Yamamoto BK, Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther. 1998 ; 287: 107-114
84. Rice-Evans CA, Diplock AT, Symons MCR Mechanisms of radical production. Burdon RH van Knippenberg PH, ed. New York, NY: Elsevier ; 1991: 19-50.
85. Rivière GJ, Gentry WB, Owens SM. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther. 2000 ; 292: 1042-1047
86. Volkow ND, Fowler JS, Wang G, Shumay E, Telang F, Thanos PK, et al. Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PLoS One. 2010 ; 5: e15269
87. Penugonda S, Mare S, Lutz P, Banks WA, Ercal N. Potentiation of lead-induced cell death in PC12 cells by glutamate: protection by N-acetylcysteine amide (NACA), a novel thiol antioxidant. Toxicol Appl Pharmacol. 2006 ; 216: 197-205
88. Banerjee A, Trueblood MB, Zhang X, Manda KR, Lobo P, Whitefield PD, et al. N-acetylcysteineamide (NACA) prevents inflammation and oxidative stress in animals exposed to diesel engine exhaust. Toxicol Lett. 2009 ; 187: 187-193
89. Lee KS, Kim SR, Park HS, Park SJ, Min KH, Lee KY, et al. A novel thiol compound, N-acetylcysteine amide, attenuates allergic airway disease by regulating activation of NF-kappaB and hypoxia-inducible factor-1 alpha. Exp Mol Med. 2007 ; 39: 756-768
90. Kawasaki T, Ishihara K, Ago Y, Nakamura S, Itoh S, Baba A, et al. Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Eur J Pharmacol. 2006 ; 542: 92-99
91. Banno M, Mizuno T, Kato H, Zhang G, Kawanokuchi J, Wang J, et al. The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia. Neuropharmacol. 2005 ; 48: 283-290
92. Wagner GC, Carelli RM, Jarvis MF. Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res Commun Chem Pathol. 1985 ; 47: 221-228
93. Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M. Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res. 2004 ; 1016: 90-95
94. Virmani A, Gaetani F, Imam S, Binienda Z, Ali S. Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity. Ann N Y Acad Sci. 2003 ; 993: 197-207
95. Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Shimizu E, et al. Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology. 2004 ; 29: 2018-2023
96. Imam SZ, El-Yazal J, Newport GD, Itzhak Y, Cadet JL, Slikker WJ, et al. Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann N Y Acad Sci. 2001 ; 939: 366-380
97. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci. 2003 ; 23: 3531-3537
98. LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addiction. 2006 ; 15: 105-110
99. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009 ; 66: 756-763
100. Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetylcysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol. 2010 ; 20: 823-828